ReviewNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2024
How should we design future mechanistic and/or efficacy clinical trials?
Review in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- Hype or hope? High placebo response in major depression treatment with ketamine and esketamine: a systematic review and meta-analysis.Frontiers in psychiatry · 2024Pooled it
- Novel multi-modal methodology to investigate placebo response in major depressive disorder.Journal of affective disorders · 2025Trial
- Modifying Informed Consent to Help Address Functional Unmasking in Psychedelic Clinical Trials.JAMA psychiatry · 2025Review
- Article
- What should constitute a control condition in psychedelic drug trials?Nature. Mental health · 2024Article
- Placebo response in RCT for antidepressant may not always be the 'villain' to fight: are KOR antagonists possibly affecting the intrinsic placebo response?Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Article
- Does serotonin matter in depression?Journal of psychiatry & neuroscience : JPNArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emergence of new molecular targets, together with the development of new approaches to neuropsychiatric diseases, involving psychedelics as well as gene and cell therapies, are creating the need to improve the efficiency of mechanistic and/or efficacy clinical trials. This review article will discuss a number of issues that have hampered our ability to detect therapeutic signals, from excessive placebo/sham response rates to the imprecision of diagnostic and outcome assessments. In addition to reviewing the limitations of current efficacy and mechanistic neuropsychiatric clinical trials, this review presents some of the methodological approaches that may improve the overall performance of our neuropsychiatric trials, including the adoption of novel study designs such as the sequential parallel comparison design and independent confirmation of the appropriateness of subjects' enrollment. In addition, this review will discuss several designs that make mechanistic clinical trials more precise.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.